Novartis med gets nod for fracture prevention

SPOTLIGHT: Novartis med gets nod for fracture prevention
Novartis said the FDA approved its bone-building drug Reclast as a treatment to prevent additional fractures following a hip fracture; the once-yearly drug's revised label includes data showing a 35 percent reduction in follow-up fractures. Report

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.